SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is currently seeing a parabolic ascent to new all-time highs, fueled by intense bullish momentum. This surge is driven by tightening global supply, notably from impending Chinese export restrictions, coupled with escalating industrial demand for EV batteries, solar, and AI data centers. The community is actively discussing a potential "silver squeeze" and a significant re-rating of silver's value relative to gold, although some participants anticipate a near-term consolidation after its rapid rally.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a recent FDA Type B meeting regarding its lead drug, Sonelokimab, with investors eagerly anticipating clarity on its path to BLA submission for Hidradenitis Suppurativa. The community is highly optimistic about Sonelokimab's "Best in Class" potential and widely discussing an imminent acquisition by Merck, with many interpreting recent insider share conversions as preparatory for a potential buyout in the $75-$90 range. Despite perceived institutional efforts to suppress the stock price, many investors remain steadfast, highlighting the drug's strong scientific data and significant market opportunity.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is currently a trending topic, largely driven by the announcement of its upcoming inclusion in the S&P MidCap 400, which has sparked widespread optimism among investors. The community is keenly focused on the company's strong positioning in the rapidly evolving "Agentic AI" sector, viewing it as a major catalyst for future growth despite some recent discussions around profit-taking and market fluctuations.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending as gold pushes to new all-time highs, fueled by escalating geopolitical concerns and expectations of continued central bank liquidity. The community is actively debating if this surge is a macro warning sign amid global monetary instability, frequently contrasting its robust performance with struggling cryptocurrencies and noting significant central bank accumulation.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is seeing a surge in conversation following new high-grade silver drill results from its Vortex system, exciting the community about the mine's significant potential. Many investors are discussing a potential silver squeeze and substantial upside, supported by rising precious metal prices and notable institutional backing from figures like Eric Sprott. Conversely, some express skepticism regarding the company's lack of current revenue, elevated technical indicators, and the possibility of future share offerings.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is drawing significant attention as its merger target, Infleqtion, garners excitement for its commercial-ready quantum sensing and timing solutions, bolstered by new partnerships in defense and tech. The investment community is actively discussing Infleqtion's perceived undervaluation compared to its quantum peers and its potential as a leader with tangible applications, especially as the anticipated merger approaches.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is trending following the closing of a US$20 million public offering, which bulls view as crucial funding for its demonstration plant and a strong signal of confidence in its Hydrochemolytic Technology. This comes amidst community discussion on the recent Shell GameChanger graduation and successful pilot trials for converting waste plastics into oil. However, skeptics continue to label the pre-revenue company as a "pump and dump," questioning its valuation and the economic viability of its technology despite ongoing partnerships and validations in the clean tech sector.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending as silver prices surge to new all-time highs, fueling community discussions about the significant disconnect between the metal's performance and the lagging silver miners. Many traders anticipate an imminent "catch-up trade" for AG, driven by expectations of increased profitability and growing industrial demand for silver despite perceived market manipulation.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is trending due to its CEO's significant share accumulation and an exceptionally low public float, igniting intense speculative interest. The community is actively discussing the stock's history of massive parabolic runs and the potential for another short squeeze, fueled by high insider ownership and a scarcity of available shares.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as investors eagerly await the FDA decision for Narsoplimab by December 26, intensified by the recently closed Novo Nordisk deal that significantly bolstered its financial position and a new share repurchase program. The community is buzzing with speculation about the approval's timing, the potential for a significant short squeeze due to high short interest, and the drug's first-in-class status for a life-threatening condition. Many believe these factors position OMER for a transformative move, with discussions also centering on the possibility of a pediatric label.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.  The company was founded in 1997 and is headquartered in Bothell, Washington.

SGEN
Seagen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGEN News

SGENSeagen Inc